DMAC Insider Trading

Insider Ownership Percentage: 7.20%
Insider Buying (Last 12 Months): $3,000,000.00
Insider Selling (Last 12 Months): $0.00

DiaMedica Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at DiaMedica Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$6M-$4M-$2M$0$2M$4M$6MTotal Insider BuyingTotal Insider Selling

DiaMedica Therapeutics Share Price & Price History

Current Price: $3.47
Price Change: Price Decrease of -0.04 (-1.14%)
As of 04/16/2025 05:00 PM ET

This chart shows the closing price history over time for DMAC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$3.47Closing price on 04/16/25:

SEC Filings (Institutional Ownership Changes) for DiaMedica Therapeutics (NASDAQ:DMAC)

10.12% of DiaMedica Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DMAC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.77Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal InflowsTotal Outflows
DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More on DiaMedica Therapeutics

Today's Range

Now: $3.47
Low: $3.28
High: $3.56

50 Day Range

MA: $5.16
Low: $3.38
High: $6.65

52 Week Range

Now: $3.47
Low: $2.14
High: $6.82

Volume

84,332 shs

Average Volume

73,377 shs

Market Capitalization

$148.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Who are the company insiders with the largest holdings of DiaMedica Therapeutics?

DiaMedica Therapeutics' top insider shareholders include:
  1. Koch Thomas Von (Major Shareholder)
  2. David J Wambeke (Insider)
  3. Randall Michael Giuffre (Director)
  4. Dietrich John Pauls (CEO)
  5. Scott Kellen (CFO)
Learn More about top insider investors at DiaMedica Therapeutics.